CALIFON, NJ - November 2, 2010 - PediatRx Inc. (a wholly owned
subsidiary of Striker Energy Corporation, OTCBB: SKRY) is pleased to announce the
launch of GRANISOL.
Dr. Cameron Durrant, the founder of PediatRx, said, "We are excited to be able to
bring this important product to market as the first commercial entry for PediatRx.
For patients undergoing chemo- or radio-therapy who may be unsuitable for other
modes of administration of granisetron, or prefer an oral liquid anti-emetic, GRANISOL
may offer an alternative. In addition, PediatRx is offering a co-pay assistance
program to help with access to GRANISOL."
GRANISOL, used to prevent nausea and vomiting, is the only granisetron available
in the USA as an orange flavored, ready-to-use oral liquid solution. GRANISOL
may be dosed once or twice daily on the day of chemo- or radio-therapy and is packaged
in a 30mL bottle containing 2mg/10mL.
Customers are able to order GRANISOL (NDC number 52547-0801-30) through their
usual channels.
About GRANISOL
Granisetron is indicated for the prevention of:
- Nausea and vomiting associated with initial and repeat courses of emetogenic cancer
therapy, including high-dose cisplatin.
- Nausea and vomiting associated with radiation, including total body irradiation
and fractionated abdominal radiation.
Selected Safety Information
- Granisetron is contraindicated in patients with known hypersensitivity to the drug
or any of its components.
- QT prolongation has been reported with granisetron. Use of GRANISOL Oral
Solution in patients concurrently treated with drugs known to prolong the QT interval
and/or are arrhythmogenic, this may result in clinical consequences.
- This drug should be used during pregnancy only if clearly needed.
- It is not known whether granisetron is excreted in human milk. Because many drugs
are excreted in human milk, caution should be exercised when granisetron is administered
to a nursing woman.
- Efficacy and safety were maintained with increasing age in the geriatric population.
- Safety and effectiveness in pediatric patients have not been established.
- The most common side effects observed with administration of granisetron were headache,
constipation, asthenia, diarrhea, abdominal pain, and dyspepsia.
About PediatRx Inc.
PediatRx Inc. is a specialty pharmaceutical company that brings prescription, branded
products to healthcare professionals for the treatment of serious medical conditions
with an initial focus on oncology supportive care.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements
are projections of events, revenues, income, future economic, research, development,
reformulation, product performance or management's plans and objectives for future
operations. In some cases you can identify forward-looking statements by the use
of terminology such as "may", "should", "anticipates", "believes", "expects", "intends",
"forecasts", "plans", "future", "strategy", or words of similar meaning. Forward-looking
statements in this press release include those concerning PediatRx’s intention to
acquire and/or license, and become the sole marketer in the United States, of other
FDA-approved, branded prescription drugs as well as reformulate certain compounds
as more appropriate forms. While these forward-looking statements and any assumptions
upon which they are based are made in good faith and reflect current judgment regarding
the direction of the business operations of PediatRx, actual results will almost
always vary, sometimes materially, from any estimates, predictions, projections,
assumptions or other future performance suggested in this press release. These statements
are predictions and involve known and unknown risks, uncertainties and other factors,
including the risk that PediatRx cannot execute its business plan for lack of capital
or other resources, distribution, partnering or licensing/acquisition opportunities,
as well as the risks described in the periodic disclosure documents filed on EDGAR
by PediatRx, copies of which are also available on the company’s website. Any of
these risks could cause PediatRx or its industry's actual results, levels of activity,
performance or achievements to be materially different from those expressed or implied
by the forward-looking statements in this press release. Except as required by applicable
law, including the securities laws of the United States, PediatRx does not intend
to update any of the forward-looking statements to conform these statements to actual
results.